Category Archives: Pharmaceutical

The Australian national publicly subsidized: DISCUSSION(4)

Given that the drug expenditures are influenced by a number of factors, not just drug prices and availability, further work needs to be done nationally to influence utilization. The National Forum on Health is examining the need for greater public … Continue reading

The Australian national publicly subsidized: DISCUSSION(3)

In Canada, the same drug may be evaluated by many different groups – myriad formulary committees – for hospitals, private drug plans, national government plans (Veterans Affairs, noninsured health benefits, Royal Canadian Mounted Police), etc, which results in much duplication … Continue reading

The Australian national publicly subsidized: DISCUSSION(2)

The structure and process of the Australian system have been criticized in the past five years. The pharmaceutical industry has viewed the PBAC system as a method of containing costs and reducing industry profit as well as imposing requirements for … Continue reading

The Australian national publicly subsidized: DISCUSSION(1)

In Canada, neither drugs nor pharmacy services are covered by the Canada Health Act. The administration of health services by statute is at the provincial level. Hence, access to drugs may vary from province to province. Provincial benefit plans may … Continue reading

The Australian national publicly subsidized: LISTING OF DRUGS FOR PAYMENT BY THE NATIONAL PBS(12)

New proposals In Australia, a new authority category has been proposed to allow prescribing of promising new drugs that have gaps in evidence of clinical effectiveness and that are used only within a randomized clinical trial. Such a method would … Continue reading

The Australian national publicly subsidized: LISTING OF DRUGS FOR PAYMENT BY THE NATIONAL PBS(11)

Drug Utilization Sub-committee The Drug Utilization Sub-committee (DUSC) of the PBAC was formed in 1988. Its terms of reference include developing mechanisms for collection, analysis and interpretation of data on drug utilization; identifying potential health problems and benefits related to … Continue reading

The Australian national publicly subsidized: LISTING OF DRUGS FOR PAYMENT BY THE NATIONAL PBS(10)

Role of the Minister and Cabinet The recommendations ofthe PBAC are provided to the Minister and then to parliament and to the Pricing Authority. The Minister cannot list a drug if the committee does not recommend listing but may alter … Continue reading

The Australian national publicly subsidized: LISTING OF DRUGS FOR PAYMENT BY THE NATIONAL PBS(9)

The committee consists of a pharmacist from the department, six medical practitioners and a pharmacist appointed by the Minister. Other members may also be appointed. The committee meets four times a year. In making listing recommendations, the committee considers the … Continue reading

The Australian national publicly subsidized: LISTING OF DRUGS FOR PAYMENT BY THE NATIONAL PBS(8)

ESC The ESC comprises members with expertise in clinical pharmacology, internal medicine, epidemiology and economics. It reviews submissions before their consideration by the PBAC. Its role is to provide review of the technical aspects of the submission (quality of trial … Continue reading

The Australian national publicly subsidized: LISTING OF DRUGS FOR PAYMENT BY THE NATIONAL PBS(7)

Pharmaceutical Evaluation Section The Pharmaceutical Evaluation Section (PES) of the Pharmaceutical Benefits Branch of the Commonwealth Health Department is responsible for the evaluation of applications for listing drugs on the PBS. It receives applications for the listing of all new … Continue reading

Pages: 1 2 Next